- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07480356
Effekt og sikkerhet av intravesikal TARA-002 sammenlignet med forskerens valg av intravesikal kjemoterapi hos deltakere med BCG-naivt høygradig ikke-muskelinvasiv blærekreft (ADVANCED-3)
En fase 3, randomisert studie for å evaluere effektiviteten og sikkerheten til intravesikal TARA-002 sammenlignet med forskerens valg av intravesikal kjemoterapi hos deltakere med BCG-naivt høggradig ikke-muskelinvasiv blærekreft
The goal of this clinical trial is to learn if TARA-002 can treat high-grade non-muscle invasive bladder cancer (NMIBC) in BCG-naïve adults 18 years of age or older.
The main questions it aims to answer are:
- Can the study drug help participants with this type of cancer?
- Is the study drug safe?
- What are the side effects of the study drug?
Researchers will compare TARA-002 to chemotherapy to see if TARA-002 works to treat NMIBC.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Chief R&D Officer
- Telefonnummer: 16468440337
- E-post: clinicaltrials@protaratx.com
Studiesteder
-
-
Arizona
-
Queen Creek, Arizona, Forente stater, 85140
- Rekruttering
- East Valley Urology Center of Arizona
-
Ta kontakt med:
- Use Central Contact
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72211
- Rekruttering
- Arkansas Urology
-
Ta kontakt med:
- Use Central Contact
-
-
California
-
Bakersfield, California, Forente stater, 93301
- Rekruttering
- Michael Oefelein Clinical Trials
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30319
- Rekruttering
- Urology of Greater Atlanta - Sandy Springs
-
Ta kontakt med:
- Use Central Contact
-
-
Missouri
-
St Louis, Missouri, Forente stater, 63110
- Rekruttering
- Renown Regional Medical Center
-
Ta kontakt med:
- Use Central Contact
-
-
South Carolina
-
Myrtle Beach, South Carolina, Forente stater, 29572
- Rekruttering
- START - Carolinas
-
Ta kontakt med:
- Use Central Contact
-
-
Texas
-
Arlington, Texas, Forente stater, 76017
- Rekruttering
- Urology Partners of North Texas
-
Ta kontakt med:
- Use Central Contact
-
Austin, Texas, Forente stater, 78745
- Rekruttering
- Urology Austin, LLC
-
Ta kontakt med:
- Use Central Contact
-
Houston, Texas, Forente stater, 77027
- Rekruttering
- Houston Metro Urology
-
Ta kontakt med:
- Use Central Contact
-
-
-
-
-
Ivano-Frankivsk, Ukraina, 76018
- Rekruttering
- Arenia - Ivano-Frankivsk
-
Ta kontakt med:
- Use Central Contact
-
Kapitanivka, Ukraina, 08111
- Rekruttering
- Arensia Kapitanivka - PPDS
-
Ta kontakt med:
- Use Central Contact
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Male or female participants 18 years of age or older at the time of signing informed consent
- Participants who have voluntarily given written informed consent after the nature of the study has been explained according to applicable requirements prior to study entry
- Central histologic confirmation of high-grade non-muscle invasive CIS (± Ta/T1) with active disease
- Participants who are BCG naive, or participants who are BCG exposed and have not received intravesical BCG for at least 24 months prior to the most recent CIS diagnosis, or participants who received ≤2 doses of BCG within the 24 months prior to the most recent CIS diagnosis
Exclusion Criteria:
- Penicillin allergy (participants with a questionable history of allergy to penicillin will undergo penicillin blood allergy testing via central laboratory
- Central confirmed variant histology
- Concomitant prostatic or upper tract urothelial involvement per Investigator's assessment
- Nodal and metastatic disease are excluded if they existed at any time (whether present or in the past)
- Any history of ≥ T2 bladder cancer that existed at any point in time in the participant's history
For more information on eligibility criteria, please contact the Sponsor.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: TARA-002 (Arm A)
|
Participants will receive 6 weekly instillations of TARA-002. Participants confirmed to have a CR at Week 12 will enter the maintenance treatment period and will receive 3 additional weekly instillations of TARA-002 every 3 months up to Month 19, and then 3 weekly doses at Month 25. Participants who are eligible for reinduction at Week 12 will receive 6 additional weekly instillations of TARA-002. Participants who undergo reinduction and are confirmed to have a CR at Week 24 will enter the maintenance regimen treatment period and will receive 3 weekly instillations of TARA-002 every 3 months up to Month 19, and then 3 weekly doses at Month 25. |
|
Aktiv komparator: Forskerens valg av intravesikal kjemoterapi
|
Participants will receive 6 weekly instillations of Investigator's choice of intravesical chemotherapy. Participants confirmed to have a CR at Week 12 will enter the maintenance regimen treatment period and will receive one intravesical instillation of Investigator's choice of intravesical chemotherapy every 1 month up to Month 25. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of high-grade complete response
Tidsramme: Month 6
|
Incidence of high-grade complete response of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy determined by cystoscopy, urine cytology, and bladder biopsy (if applicable) |
Month 6
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Duration of high-grade complete response
Tidsramme: Up to Month 60
|
Duration of high-grade complete response of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Treatment emergent adverse events
Tidsramme: Up to Month 60
|
Incidence and severity of treatment emergent adverse events (TEAEs) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Treatment emergent serious adverse events
Tidsramme: Up to Month 60
|
Incidence and severity of treatment emergent serious adverse events (TESAEs) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
High-grade complete response rate
Tidsramme: At Months 3, 9, 12, 15, 18, 21, 24, 27, 30, 36, 42, 48, 54, and 60
|
High-grade complete response rate of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy determined by cystoscopy, urine cytology, and bladder biopsy (if applicable) |
At Months 3, 9, 12, 15, 18, 21, 24, 27, 30, 36, 42, 48, 54, and 60
|
|
High-grade complete response rate (CIS only)
Tidsramme: Month 6
|
High-grade complete response rate of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy determined by cystoscopy, urine cytology, and bladder biopsy (if applicable) in sub-group of participants with CIS only |
Month 6
|
|
Event-free survival
Tidsramme: Up to Month 60
|
Event-free survival (EFS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Recurrence-free survival
Tidsramme: Up to Month 60
|
Recurrence-free survival (RFS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Progression-free survival
Tidsramme: Up to Month 60
|
Progression-free survival (PFS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Disease-specific progression-free survival
Tidsramme: Up ro Month 60
|
Disease-specific progression-free survival (DSPFS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up ro Month 60
|
|
Overall survival
Tidsramme: Up to Month 60
|
Overall survival (OS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Disease-specific survival
Tidsramme: Up to Month 60
|
Disease-specific survival (DSS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Time to cystectomy
Tidsramme: Up to Month 60
|
Time to cystectomy of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Time to recurrence delayed cystectomy
Tidsramme: Up to Month 60
|
Time to recurrence delayed cystectomy of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Time to progression
Tidsramme: Up to Month 60
|
Time to progression of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
|
Time to disease worsening
Tidsramme: Up to Month 60
|
Time to disease worsening of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy |
Up to Month 60
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Mannlige urogenitale sykdommer
- Urologiske sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Neoplasmer etter histologisk type
- Neoplasmer, kjertel og epitel
- Urologiske neoplasmer
- Karsinom
- Urinblæresykdommer
- Ikke-muskelinvasive blære-neoplasmer
- Neoplasmer
- Karsinom in situ
- Neoplasmer i urinblæren
Andre studie-ID-numre
- TARA-002-301
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .